The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide

dc.contributor.authorRozados, Viviana R.
dc.contributor.authorMainetti, Leandro Ernesto
dc.contributor.authorRico, María José
dc.contributor.authorZacarías Fluck, Mariano
dc.contributor.authorMatar, Pablo
dc.contributor.authorScharovsky, O. Graciela
dc.date.accessioned2012-08-27T15:00:48Z
dc.date.available2012-08-27T15:00:48Z
dc.date.issued2010-11-01
dc.description.abstractMetronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an antiangiogenic effect. It refers to regular administration of low doses of cytotoxic drugs, with minimal or no drug-free breaks. Previously, we demonstrated the immunomodulating activity of a single low-dose of cyclophosphamide (Cy) and the antitumor effect of MCT with Cy on established rat lymphomas and sarcomas. Here, we examined whether the immune response is responsible for the antitumor effect of MCT with Cy on L-TACB lymphoma. Inbred e rats and nude mice were subcutaneously challenged with L-TACB. After 7 days, they were distributed into two experimental groups: 1) treated animals, which were injected IP with Cy (10 mg/kg body weight) three times per week, and 2) control animals, which received IP saline injections. Exponential growth and decay and tumor doubling time were calculated. Also, serum IL-10 levels were measured. One hundred percent of treated rats showed tumor regression versus 0% of control rats. The increase of tumor-induced IL-10 levels was reverted by the treatment with Cy. On the other hand, there were no tumor regressions, in treated or control nude mice. However, the tumor doubling times of treated nude mice were significantly higher than those of control mice, implying that other antitumor mechanism(s), independent of the adaptive immune response, might be taking place. Our present results indicate that modulation of the immune response would be involved in the antitumor effect of MCT with Cy, because the absence of the specific immune response impairs, at least in part, its therapeutic effect in a lymphoma tumor model.es
dc.description.peerreviewedPeer reviewedes
dc.description.sponsorshipUniversidad Nacional de Rosarioes
dc.formatapplication/pdf
dc.identifier.citationRozados, V. R., Mainetti, L. E., Rico, M. J., Zacarias, F. M. F., Matar, P., & Scharovsky, O. G. (September 27, 2010). The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncology Research, 18, 601-605. DOI: 10.3727/096504010X12777678141662es
dc.identifier.doihttp://dx.doi.org/10.3727/096504010X12777678141662
dc.identifier.issn1555-3906
dc.identifier.urihttp://hdl.handle.net/2133/2011
dc.language.isoenes
dc.publisherCognizant Communication Corporationes
dc.relation.publisherversionhttp://dx.doi.org/10.3727/096504010X12777678141662es
dc.rightsopenAccess
dc.rights.text© 2010 Cognizant Comm. Corp.es
dc.subjectMetronomic chemotherapyes
dc.subjectImmune responsees
dc.subjectLymphomaes
dc.subjectCyclophosphamidees
dc.subject.meshAntineoplastic Agents, Alkylating/therapeutic use
dc.subject.meshCyclophosphamide/therapeutic use
dc.subject.meshInterleukin-10/blood
dc.subject.meshLymphoma/drug therapy
dc.subject.meshLymphoma/immunology
dc.titleThe Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamidees
dc.typearticle
dc.typeartículo
dc.typepublishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Oncol Res 2010.pdf
Tamaño:
68.97 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
0 B
Formato:
Item-specific license agreed upon to submission
Descripción: